LONDON--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the international molecular diagnostics company announces the launch of a genetic test for CYP450 2C9 drug metabolism. CYP450 2C9, or CYP2C9, is an important member of the Cytochrome P450 family of enzymes responsible for detoxifying potentially hazardous chemicals, such as drugs, that are “foreign“ to the body. The CYP2C9 gene is important in its involvement in the metabolism of 10% of all drugs, including non-steroidal anti-inflammatory drugs (e.g. celecoxib, ibuprofen), anti-coagulants (e.g. warfarin), anti-epileptic agents (e.g. phenytoin), cholesterol-lowering drugs (statins / e.g. fluvastatin) and anti-diabetic agents (e.g. aprepitant).
